L. Mansi and A. Thiery-vuillemain, Safety profile of new anticancer drugs, Expert Opinion on Drug Safety, vol.9, issue.18, pp.301-317, 2010.
DOI : 10.1128/MCB.24.1.200-216.2004

URL : https://hal.archives-ouvertes.fr/inserm-00484832

F. Michaïlesco and . Bilan-démographique, Région Réunion. Insee Disponible sur http://www.insee.fr/fr/themes/document.asp?ref_id=19625. (3) Présentation de la région. Insee Réunion. Disponible sur http, 2011.

. Tableau-de-bord, Les cancers à La Réunion, Observatoire Régional de Santé La Réunion, pp.15-16, 2009.

C. Duchemann, M. Ricquebourg, and N. Lettre, Observatoire Régional de Santé La Réunion, 2012.

C. Bernede-bauduin, C. Duchemann, and N. Lettre, Observatoire Régional de Santé La Réunion 2012. (10) Bernede-Bauduin C. Tableau de Bord sur le diabète à La Réunion, Observatoire Régional de Santé La Réunion, vol.pp, issue.11, pp.10-12, 2012.

A. Schechter, M. Hung, and L. Vaidyanathan, The neu gene: an erbB-homologous gene distinct from and unlinked to the gene encoding the EGF receptor, Science, vol.229, issue.4717, pp.976-978, 1985.
DOI : 10.1126/science.2992090

D. Slamon, G. Clark, and S. Wong, Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene, Science, vol.235, issue.4785, 1987.
DOI : 10.1126/science.3798106

D. Slamon, W. Godolphin, and L. Jones, Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer, Science, vol.244, issue.4905, pp.707-712, 1989.
DOI : 10.1126/science.2470152

R. Natha and F. Esteva, HER-2-targeted therapy : lessons learned and future directions

T. Fujita, H. Doihara, and K. Kawasaki, PTEN activity could be a predictive marker of trastuzumab efficacy in the treatment of ErbB2-overexpressing breast cancer, British Journal of Cancer, vol.57, issue.2, pp.247-252, 2006.
DOI : 10.1038/sj.onc.1203972

N. Spector and K. Blacwell, Understanding the Mechanisms Behind Trastuzumab Therapy for Human Epidermal Growth Factor Receptor 2???Positive Breast Cancer, Journal of Clinical Oncology, vol.27, issue.34, pp.5838-5847, 2009.
DOI : 10.1200/JCO.2009.22.1507

A. Petit, J. Rak, and M. Hung, Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothélial growth factor production by tumor cells in vitro and in vivo : angiogenic implications for signal transduction therapy of solide tumors, Am J Pathol, vol.151, issue.246, pp.1523-1530, 1997.

J. Baselga, J. Albanell, and M. Molina, Mechanism of action of trastuzumab and scientific update, Seminars in Oncology, vol.28, issue.255, pp.4-11, 2001.
DOI : 10.1016/S0093-7754(01)90276-3

J. Albanell, J. Codony, and A. Rovira, Mechanism of Action of Anti-Her2 Monoclonal Antibodies: Scientific Update on Trastuzumab and 2c4, Adv Exp Med Biol, vol.532, pp.253-268, 2003.
DOI : 10.1007/978-1-4615-0081-0_21

D. Slamon, L. , B. Shak, and S. , Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2, Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER, 2001.
DOI : 10.1056/NEJM200103153441101

M. Marty, F. Cognetti, and D. Maranchini, Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor2-positive metastatic breast cancer administred as first line treatment: The M77001 Study Group, J Clin Oncol, vol.23, 2005.

B. Kauffman, J. Mackey, and M. Clemens, Trastuzumab plus anastrozole versus anastrozole alone for the treatment of post-menopausal women with Human epidermal growth factor receptor2-positive, hormone receptor positive metastatic breast cancer : results from the randomized phase III TAnDEM study Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally Advanced human epidermal growth factor receptor 2-positive breast cancer : The HERNATA study Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer : the CLEOPATRA Study Group, 34) Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer, pp.29-33, 2005.

E. Romond, E. Perez, and J. Bryant, Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer, New England Journal of Medicine, vol.353, issue.16, 2005.
DOI : 10.1056/NEJMoa052122

D. Slamon, W. Eiermann, and N. Robert, Phase III randomized trial comparing doxorubicine and cyclophosphamide followed by docetaxel with doxorubicine and cyclophosphamide followed by docetaxel and trastuzumab with docetaxel, carboplatin and trastuzumab in HER2-postive early breast cancer patients : BCIRG 006 study, Brest Cancer Res Treat, vol.94, issue.36, 2005.

D. Slamon, W. Eiermann, and N. Robert, Adjuvant Trastuzumab in HER2-Positive Breast Cancer, New England Journal of Medicine, vol.365, issue.14, pp.1273-1283, 2011.
DOI : 10.1056/NEJMoa0910383

M. Telli, S. Hunt, and R. Carlson, Trastuzumab related cardiotoxicity : calling into question of reversibility Independant adjudication of symptomatic heart failure with use of doxorubicin and cylophosphamide followed by trastuzumab adjuvant therapy : A combined review of cardiac data from the National Surgical Adjuvant Breast and Bowel Project B-31 and the North Central Cancer treatment Group N9831 clinical trials, J Clin Oncol J Clin Oncol, vol.25, issue.28, pp.3526-3567, 2007.

M. Procter, T. Suter, and E. De-azambuja, Longer-Term Assessment of Trastuzumab-Related Cardiac Adverse Events in the Herceptin Adjuvant (HERA) Trial, Journal of Clinical Oncology, vol.28, issue.21, pp.3422-3428, 2010.
DOI : 10.1200/JCO.2009.26.0463

M. Grenier and S. Lipshultz, Epidemiology of anthracycline cardiotoxicity in children and adults (44) Cook-Bruns N. Rétrospective analysis of the safety of Herceptin immunotherapy in metastatic breast cancer, Semin Oncol Oncology, vol.25, issue.61 2, pp.72-85, 1998.

M. Marty, J. Baselga, and U. Gatzemeier, Changes in left ventricular éjection fraction (LVEF) during trastuzumab therapy: A pooled analysis of four trials Cardiac tolérance of the combination pacltaxel-anthracyclines in the context of the management of cancer of the breast Cardiovascvular complications of cancer therapy: incidence, pathogenesis, diagnosis,and management years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomized controlled trial, Proc Am Soc Clin Oncol Bull Cancer J Am Coll Cardiol Lancet, vol.90, issue.382, pp.72-118, 2003.

H. Joensuu, P. Kellokumpu-lehtinen, and P. Bono, Adjuvant Docetaxel or Vinorelbine with or without Trastuzumab for Breast Cancer, New England Journal of Medicine, vol.354, issue.8, 2006.
DOI : 10.1056/NEJMoa053028

E. Tan-chiu, G. Yothers, and E. Romond, Assessment of Cardiac Dysfunction in a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed By Paclitaxel, With orWithout trastuzumab As Adjuvant Therapy in Node-Positive, Human Epidermal Growth Factor Receptor 2-Overexpressing Breast cancer : NSABP B-31 Reversibility of Trastuzumab-Related Cardiotoxicity: New Insights Based on Clinical Course and Response to Medical Treatment, J Clin Oncol vol J Clin Oncol, vol.50, issue.2331, pp.809-8207811, 2005.

N. Freedman and G. Ginsburg, Novel???and ???Neu??????Therapeutic Possibilities for Heart Failure??????Editorials published in the Journal of the American College of Cardiologyreflect the views of the authors and do not necessarily represent the views of JACCor the American College of Cardiology., Journal of the American College of Cardiology, vol.48, issue.7, pp.1448-1450, 2006.
DOI : 10.1016/j.jacc.2006.07.005

Y. Zhao, D. Sawyer, and R. Baliga, Neureglins promot survival and growth of cardiac myocytes. Persitance of ErbB2 and ErbB4 expression in néonatal and adult ventricular myocytes Neuregulin receptors erbB2 and erbB4 in failing human myocardium-depressed expression and atenuated activation, J Biol Chem Basic Res Cardiol, vol.273, issue.100, pp.10261-10269, 1998.

S. Rohrbach, X. Yan, and E. Weinberg, Neuregulin in cardiac hypertrophy in rats with aortic stenosis. Differencial expression of erbB2 and erbB4 receptor Death begets failure in the heart, Circulation J Clin Invest, vol.100, issue.115, pp.407-412, 1999.

Z. Yan, O. Tschopp, and N. Di-poi, Dosage-dépendant effects of Akt/protein kinase Balpha (PKBalpha) and Akt3/PKBgamma on thymus, skin and cardiovascular and nervous system development in mice, Mol Cell Biol, vol.25, pp.10407-10418, 2005.

K. Chien, Herceptin and the Heart ??? A Molecular Modifier of Cardiac Failure, New England Journal of Medicine, vol.354, issue.8, pp.789-790, 2006.
DOI : 10.1056/NEJMp058315

E. Perez, V. Suman, and N. Davidson, Cardiac Safety Analysis of Doxorubicin and Cyclophosphamide Followed by Paclitaxel With or Without Trastuzumab in the North Central Cancer Treatment Group N9831 Adjuvant Breast Cancer Trial, Journal of Clinical Oncology, vol.26, issue.8, pp.1231-1238, 2008.
DOI : 10.1200/JCO.2007.13.5467

M. Castel, F. Despas, and A. Modesto, Effets indésirables cardiaques des chimiothérapies. La presse Médicale Disponible sur http, pp.26-39, 2013.

C. Elalouani, Cardiotoxicit?? ?? court et ?? moyen terme des anthracyclines??: ??tude prospective, Annales de Cardiologie et d'Ang??iologie, vol.61, issue.4, 2012.
DOI : 10.1016/j.ancard.2012.03.004

D. Cardinale, M. Sandri, and A. Martinoni, Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy, J Am Coll Cardiol, vol.34, pp.517-522, 2000.

D. Cardinale, M. Sandri, and A. Martinoni, Myocardial injury revealed by plasma troponin I in breast cancer treated with high-dose chemotherapy, Annals of Oncology, vol.13, issue.5, pp.710-715, 2002.
DOI : 10.1093/annonc/mdf170

H. Okumura, K. Luchi, and T. Yoshida, Brain natriuretic peptide is a predictor of anthracyline-induced cardiotoxicity Simultaneous hemodynamic and serological cardiotoxicity during immunotherapy with trastuzumab, Acta Haematol Int J Cardiol, vol.103, issue.65, pp.158-163, 2000.

. Disponible-sur, C. Benz, G. Scott, and J. Sarup, Estrogen-dependant, tamoxifen-resistant tumorogenic growth of MCF-7 cells transfected with HER2/neu, Breast Cancer Res Treat, vol.24, issue.67, pp.85-95, 1992.

V. Chazin, M. Kaleko, and A. Miller, Transformation mediated by the human HER- 2 gene indépendant of epidermal growth factor receptor, Oncongene, vol.7, issue.68, pp.18-66, 1992.